Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01963728 · ClinicalTrials.gov registry record · Phase 4
Comparison of Insulin Therapy in Treating Post-Transplant Diabetes
A Phase 4 study, sponsored by Inova Health Care Services.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT01963728: Clinical Trial Phase 4 study, sponsored by Inova Health Care Services.
NCT01963728 is a Phase 4 study that was terminated before completion, run by Inova Health Care Services. The registered enrollment target is 2 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01963728, a Phase 4 study, was terminated before completion, sponsored by Inova Health Care Services.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
To determine if the use of insulin isophane results in improved control of blood sugars compared to the use of insulin glargine in new onset diabetes after kidney, lung, or heart transplantation (NODAT).
Interventions
- DRUG insulin glargine
- DRUG Insulin, Isophane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-11-27 |
| Est. Completion | 2015-04-09 |
| Phase | Phase 4 |
Why NCT01963728 stopped before completion
NCT01963728 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which insulin glargine is the first listed.
NCT01963728 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01963728 about?
NCT01963728 is a clinical study titled "Comparison of Insulin Therapy in Treating Post-Transplant Diabetes". To determine if the use of insulin isophane results in improved control of blood sugars compared to the use of insulin glargine in new onset diabetes after kidney, lung, or heart transplantation (NODAT).
What is the current status of trial NCT01963728?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2013-11-27. Estimated completion is 2015-04-09.
What interventions are being tested in trial NCT01963728?
The interventions under investigation include: insulin glargine (DRUG), Insulin, Isophane (DRUG).
Who is sponsoring clinical trial NCT01963728?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01963728's enrollment target sits among peer trials
2 1998th of 2000 higher than 1 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI